The experiment showed that recipient mice receiving transplants from CCR6-deficient donors experienced delayed onset and relatively mild symptoms of acute GVHD, suggesting that CCR6 may be a potential chemokine receptor target for the prevention and treatment of acute GVHD (72). Here, CCR6 is linked to acute graft versus host disease.